Acid ‐suppressive drugs: A systematic review and network meta‐analysis of their nocturnal acid‐inhibitory effect
ConclusionsThis is the first study to compare the effect of ASDs on inhibiting nocturnal acid breakthrough. Overall, in terms of nocturnal acid-inhibitory effect, vonoprazan and tegoprazan had an advantage against other regimens including H2RAs, isomer PPIs, traditional PPIs, AHB, and new PPIs. Even in some subgroups, such as language classification (English), types of study design (crossover-RCT), age ( ≤40 years), BMI (18.5-24.9 kg/m2), continent (Asia and North America), disease status (health), the duration of therapy (2 weeks), and time of administration (at daytime or at night-time), the nocturnal acid-inhibit...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 5, 2023 Category: Drugs & Pharmacology Authors: Shupeng Zou,
Mengling Ouyang,
Qian Cheng,
Xuan Shi,
Minghui Sun Tags: RESEARCH ARTICLE Source Type: research
[ASAP] Precise Control of the Oxidation Reaction in a High-Purity Dexlansoprazole Synthesis Process Using < italic toggle="yes" > In Situ < /italic > Infrared
Organic Process Research& DevelopmentDOI: 10.1021/acs.oprd.3c00098 (Source: Organic Process Research and Development)
Source: Organic Process Research and Development - May 27, 2023 Category: Chemistry Authors: Chunchao Wang, Haoyu Wang, Cheng Huang, Chengjun Wu, and Tiemin Sun Source Type: research
Improving clinical outcomes of Barrett's esophagus with high dose proton pump inhibitors and cryoablation
CONCLUSIONS: Minimizing acid reflux with at least PPI-BID combined with CRYO ablation appears to be the optimal cost-effective and safe BE treatment for any stage to minimize progression to adenocarcinoma by addressing both the stimulus that causes BE and the presence of goblet cells.PMID:37232568 | DOI:10.1080/07853890.2023.2191002 (Source: Annals of Medicine)
Source: Annals of Medicine - May 26, 2023 Category: Internal Medicine Authors: Harry Snady Source Type: research
Protective effects of esomeprazole against cisplatin-induced ototoxicity: an in vitro and in vivo study
In this study, we aimed to identify novel compounds that could afford protection against cisplatin-induced ototoxicity by employing both cell- and zebrafish (Danio rerio)-based screening platforms. We screened 923 US Food and Drug Administration-approved drugs to identify potential compounds exhibiting protective effects against cisplatin-induced ototoxicity in HEI-OC1 cells (auditory hair cell line). The screening strategy identified esomeprazole and dexlansoprazole as the primary hit compounds. Subsequently, we examined the effects of these compounds on cell viability and apoptosis. Our results revealed that esomeprazole...
Source: Aquatic Toxicology - May 21, 2023 Category: Toxicology Authors: Hanul Jeon In Sik Song Jin-Gyeong Park Hyejin Lee Eunjung Han Saemi Park Yunkyoung Lee Chi-Man Song Wooyoung Hur In-Gyun Lee June Choi Source Type: research
Protective effects of esomeprazole against cisplatin-induced ototoxicity: an in vitro and in vivo study
In this study, we aimed to identify novel compounds that could afford protection against cisplatin-induced ototoxicity by employing both cell- and zebrafish (Danio rerio)-based screening platforms. We screened 923 US Food and Drug Administration-approved drugs to identify potential compounds exhibiting protective effects against cisplatin-induced ototoxicity in HEI-OC1 cells (auditory hair cell line). The screening strategy identified esomeprazole and dexlansoprazole as the primary hit compounds. Subsequently, we examined the effects of these compounds on cell viability and apoptosis. Our results revealed that esomeprazole...
Source: Aquatic Toxicology - May 21, 2023 Category: Toxicology Authors: Hanul Jeon In Sik Song Jin-Gyeong Park Hyejin Lee Eunjung Han Saemi Park Yunkyoung Lee Chi-Man Song Wooyoung Hur In-Gyun Lee June Choi Source Type: research
Protective effects of esomeprazole against cisplatin-induced ototoxicity: an in vitro and in vivo study
In this study, we aimed to identify novel compounds that could afford protection against cisplatin-induced ototoxicity by employing both cell- and zebrafish (Danio rerio)-based screening platforms. We screened 923 US Food and Drug Administration-approved drugs to identify potential compounds exhibiting protective effects against cisplatin-induced ototoxicity in HEI-OC1 cells (auditory hair cell line). The screening strategy identified esomeprazole and dexlansoprazole as the primary hit compounds. Subsequently, we examined the effects of these compounds on cell viability and apoptosis. Our results revealed that esomeprazole...
Source: Aquatic Toxicology - May 21, 2023 Category: Toxicology Authors: Hanul Jeon In Sik Song Jin-Gyeong Park Hyejin Lee Eunjung Han Saemi Park Yunkyoung Lee Chi-Man Song Wooyoung Hur In-Gyun Lee June Choi Source Type: research
Protective effects of esomeprazole against cisplatin-induced ototoxicity: an in vitro and in vivo study
In this study, we aimed to identify novel compounds that could afford protection against cisplatin-induced ototoxicity by employing both cell- and zebrafish (Danio rerio)-based screening platforms. We screened 923 US Food and Drug Administration-approved drugs to identify potential compounds exhibiting protective effects against cisplatin-induced ototoxicity in HEI-OC1 cells (auditory hair cell line). The screening strategy identified esomeprazole and dexlansoprazole as the primary hit compounds. Subsequently, we examined the effects of these compounds on cell viability and apoptosis. Our results revealed that esomeprazole...
Source: Aquatic Toxicology - May 21, 2023 Category: Toxicology Authors: Hanul Jeon In Sik Song Jin-Gyeong Park Hyejin Lee Eunjung Han Saemi Park Yunkyoung Lee Chi-Man Song Wooyoung Hur In-Gyun Lee June Choi Source Type: research
Protective effects of esomeprazole against cisplatin-induced ototoxicity: an in vitro and in vivo study
In this study, we aimed to identify novel compounds that could afford protection against cisplatin-induced ototoxicity by employing both cell- and zebrafish (Danio rerio)-based screening platforms. We screened 923 US Food and Drug Administration-approved drugs to identify potential compounds exhibiting protective effects against cisplatin-induced ototoxicity in HEI-OC1 cells (auditory hair cell line). The screening strategy identified esomeprazole and dexlansoprazole as the primary hit compounds. Subsequently, we examined the effects of these compounds on cell viability and apoptosis. Our results revealed that esomeprazole...
Source: Aquatic Toxicology - May 21, 2023 Category: Toxicology Authors: Hanul Jeon In Sik Song Jin-Gyeong Park Hyejin Lee Eunjung Han Saemi Park Yunkyoung Lee Chi-Man Song Wooyoung Hur In-Gyun Lee June Choi Source Type: research
Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study
CONCLUSIONS: All the tegoprazan groups demonstrated a significantly faster onset of gastric pH increase and longer holding times above pH >4 and pH >6 up to 12 hours after evening dosing than the dexlansoprazole group.PMID:36317518 | DOI:10.5009/gnl220050 (Source: Gut and Liver)
Source: Gut and Liver - November 1, 2022 Category: Gastroenterology Authors: Sungpil Han Hee Youn Choi Yo Han Kim SeungChan Choi Seokuee Kim Ji Yeon Nam Bongtae Kim Geun Seog Song Hyeong-Seok Lim Kyun-Seop Bae Source Type: research
Dexlansoprazole prevents pulmonary artery hypertension by inhibiting pulmonary artery smooth muscle cell to fibroblast transition
CONCLUSIONS: Dexlansoprazole can prevent PAH through promoting cGMP generation and inhibiting pulmonary vascular remodeling through restraining PASMCs' proliferation, migration, and phenotypic transition to fibroblast-like cells. Consequently, PAH might be a new indication for dexlansoprazole.PMID:36105026 | PMC:PMC9452313 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - September 15, 2022 Category: Research Authors: Qian Jiao Fangdi Zou Shiliang Li Jiawen Wang Yunping Xiao Zhihua Guan Liang Dong Jinwei Tian Shengqing Li Rui Wang Jian Zhang Honglin Li Source Type: research
